·10 min read·compound-guide
On the FDA horizon: 6 peptides likely to land 2026-2028, and what each one changes
Retatrutide, orforglipron, CagriSema, survodutide, MariTide, pemvidutide. Where each one sits in phase 3, the readout window, the mechanism, and what each approval would shift for routing decisions today. Bleeding edge of the science, conservative on the rating.